340B Program, Explained: How Manufacturers Should Respond
The 340B program is a critical provision for the pharmaceutical industry, one that has now shaped...
Read the article
Innovative Rheumatoid Arthritis Therapy
Bringing a novel therapy to market is no small feat, especially in a landscape dominated by well-established treatments. Read how a data-driven value story reshaped payer perceptions to achieve 99% commercial insurance coverage, broad support from all major payers, and rapid prescriber uptake.
Read the story